FORCE - Facing Our Risk of Cancer Empowered  University of South Florida

Early Detection

Does adding other biomarker test to CA125 and transvaginal ultrasound increase early detection of ovarian cancer in high-risk women?

There is broad agreement among experts that women with very high risk for ovarian cancer should undergo risk-reducing removal of their ovaries and fallopian tubes (also known as risk-reducing salpingo-oophorectomy, or RRSO), the timing of surgery depends on the genetic mutation. High risk women who are not ready to undergo surgery are sometimes followed with high risk screening consisting of CA125 and transvaginal ultrasound. These tests are not very accurate; false positive/negative tests are common. Even with screening, most women who develop ovarian cancer are not found at an early enough stage to improve their survival. Newer tests have been developed to try to detect ovarian cancer at an earlier stage. These tests have not been studied for screening of high risk women. This research questions proposes designing a study to see if the addition of a new blood test to current screening guidelines improves early detection of ovarian cancer.

Research Prioritization Process

ABOUT's patient-driven research process, known as "GAP360" takes unanswered medical questions submitted by the community and turns them into well-defined research questions that can be answered through ABOUT research. GAP stands for Generate, Assess, Prioritize, Plan, Perform, and Publish — the steps that are involved in this process.

Submit your research questions

Woman submitting question

Search Research Questions

By Keyword:

  

ABOUT is a Patient-Powered Research Network in PCORnet®,  the National Patient-Centered Clinical Research Network, an initiative funded by the Patient-Centered Outcomes Research Institute (PCORI).

The National Patient-Centered Clinical Research Network
  Find Us on Twitter

© FORCE: Facing Our Risk of Cancer Empowered Inc. info@facingourrisk.org

Website by Rareheron Web Design